Bruker Corporation Press Releases https://ir.bruker.com/generated by Q4Sat, 22 Aug 2026 14:28:04 -0400Copyright Q4 Inc. All rights reserved.Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratoriesd555ab26-6c6e-4b46-b119-b484926fb510https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Announces-Strategic-Collaboration-with-Atinary-Technologies-to-Advance-Self-Driving-Laboratories/default.aspxTue, 11 Aug 2026 07:00:00 -0400Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Developmentf6739629-6e8f-4dbd-bc87-eb94b19ed12ehttps://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Announces-Majority-Investment-in-MIMETAS-to-Advance-Human-Physiology-Relevant-Drug-Discovery-and-Development/default.aspxMon, 10 Aug 2026 07:00:00 -0400Bruker Reports Second Quarter 2026 Financial Results3b0d4a7a-c0f2-4636-bb2b-53c34b32061bhttps://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Reports-Second-Quarter-2026-Financial-Results/default.aspxTue, 04 Aug 2026 07:00:00 -0400Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast5389c939-e4f6-4adc-b79e-ef671b462d5chttps://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Announces-Date-and-Time-of-Second-Quarter-2026-Earnings-Release-and-Webcast/default.aspxFri, 24 Jul 2026 16:01:00 -0400Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Bloodc6e4e119-c979-470c-a72b-de7fa2681189https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Expands-Infection-Detection-Portfolio-with-Acquisition-of-Metagenomic-mNGS-DISQVER-Platform-for-Pathogenic-Microorganisms-in-Blood/default.aspxWed, 15 Jul 2026 07:00:00 -0400Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026e28b3098-9394-46df-9357-fc4103c3cc97https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Showcases-Expanding-Microbiology--Infection-Diagnostics-Portfolio-at-ASM-Microbe-2026/default.aspxThu, 04 Jun 2026 07:00:00 -0400Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry35ed20e7-4c80-44a9-80dd-eab3f0c36447https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Launches-new-timsMRMS-Mass-Spectrometry-Platform-for-Unique-Ultra-Complex-Mixture-Applications-in-the-Energy-Industry/default.aspxTue, 02 Jun 2026 11:24:00 -0400Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology000e11df-6563-4dda-8a57-1ac679cb8692https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Announces-Major-Strides-in-4D-Proteomics-Performance-Further-Advances-In-Intact-and-Top-Down-Functional-Proteoform-Analysis-and-Innovations-in-Hybrid-QualQuant-4D-Metabolomics--all-to-Enable-Deeper-Insights-into-Disease-Biology/default.aspxMon, 01 Jun 2026 07:00:00 -0400Champalimaud Foundation’s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI6a651e25-2dec-4a72-9ac6-c66d69c5b098https://ir.bruker.com/press-releases/press-release-details/2026/Champalimaud-Foundations-Neuroscience-and-Oncology-Research-Benefits-from-18-Tesla-Ultra-High-Field-MRI/default.aspxTue, 26 May 2026 07:00:00 -0400Bruker Reports First Quarter 2026 Financial Resultsdd7626c4-43b3-4d8d-8d5b-51d0df4d0febhttps://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Reports-First-Quarter-2026-Financial-Results/default.aspxWed, 06 May 2026 06:30:00 -0400